Omadacycline (tosylate)

Omadacycline (tosylate)

• CAS Number: 1075240-43-5
• UNSPSC Description: Omadacycline (PTK 0796) tosylate, a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline tosylate acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline tosylate possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline tosylate can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections[1][2][3][4].
• Target Antigen: Antibiotic; Bacterial
• Type: Reference compound
• Related Pathways: Anti-infection
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Assay Protocol: https://www.medchemexpress.com/omadacycline-tosylate.html
• Solubility: H2O : 12.5 mg/mL (ultrasonic)
• Smiles: O=C(C1=C(O)[C@@H](N(C)C)[C@@](C[C@@]2([H])C(C(C3=C(O)C(CNCC(C)(C)C)=CC(N(C)C)=C3C2)=O)=C4O)([H])[C@@]4(O)C1=O)N.OS(=O)(C5=CC=C(C)C=C5)=O
• Molecular Weight: 728.85
• References & Citations: [1]Durães F, et, al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals (Basel). 2019 Apr 21;12(2):63.|[2]Macone AB, et, al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127-35.|[3]Zhanel GG, et, al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313.|[4]Markham A, et, al. Omadacycline: First Global Approval. Drugs. 2018 Dec;78(18):1931-1937.|[5]Tanaka SK, et al. In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5247-53. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0063824.|Animal Feed Science and Technology. 2014 Dec;198:323-332.|Ann Lab Med. 2021 May 1;41(3):293-301.|Antibiotics (Basel). 2022, 11(10), 1298.|Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19.|Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02097-19.|Antimicrob Agents Chemother. 2023 Jan 23;e0145922.|Clin Exp Pharmacol Physiol. 2023 Apr 22.|Comput Intell Neurosci. 2022 Apr 25;2022:7636983.|Diagn Micr Infec Dis. 2020 Nov;98(3):115129.|J Antibiot (Tokyo). 2022 Jun 27.|J Clin Microbiol. 2020 Jan 28;58(2):e01603-19.|Microbiol Spectr. 2022 Dec 8;e0323822.|Microbiol Spectr. 2023 May 4;e0071823.|Nat Microbiol. 2023 Mar;8(3):410-423.|Nat Struct Mol Biol. 2023 Aug 7.|Open Forum Infect Dis. 2024 Oct 11;11(11):ofae611.|PLoS Biol. 2022 Sep 28;20(9):e3001808.|Research Square Preprint. 2020 Jun.|J Antimicrob Chemother. 2021 Feb 11;76(3):653-658.|J Antimicrob Chemother. 2021 May 6;dkab141.|Virulence. 2022 Dec;13(1):77-88.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched